Uniquity Bio

Uniquity Bio is a clinical-stage drug development company focused on immunology and inflammation, actively building a pipeline of immunology and inflammation products. Its first major asset is solrikitug, a monoclonal antibody targeting TSLP. The company expects to deliver first-in-class efficacy across multiple respiratory and gastrointestinal indications with significant unmet needs.